Physician profile
John Lavery
NPI 1740239227
$48,701.24
in general payments reported to CMS, 2019-2025
50 companies · $9,380 in 2025
The $9,380 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,708 · 2020: $6,797 · 2021: $3,823 · 2022: $5,881 · 2023: $5,604 · 2024: $12K · 2025: $9,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $11K · Travel and Lodging: $1,073 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,701.48 |
| Consulting Fee | $10,575.00 |
| Travel and Lodging | $1,072.66 |
| Education | $142.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,122.18 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $7,374.33 | 2019-2025 | Orencia |
| Abbvie INC. | $6,490.57 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $3,253.92 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $2,646.79 | 2019-2023 | Krystexxa |
| Pfizer INC. | $2,516.55 | 2019-2025 | |
| Eli Lilly and Company | $2,475.00 | 2022 | |
| Glaxosmithkline, LLC. | $1,859.50 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $1,558.55 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,295.80 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $1,104.27 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,050.90 | 2019-2025 | |
| Lilly USA, LLC | $978.74 | 2019-2024 | Taltz |
| Janssen Scientific Affairs, LLC | $580.41 | 2019-2024 | Tremfya |
| Collegium Pharmaceutical, INC. | $549.11 | 2019-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $505.47 | 2019-2024 | Actemra, Rituxan |
| Genzyme Corporation | $459.24 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $443.49 | 2023-2025 | Strensiq |
| Ani Pharmaceuticals, INC. | $366.16 | 2023-2024 | Purified Cortrophin Gel |
| Arbor Pharmaceuticals, INC. | $266.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.17 | 2021-2024 | Cyltezo |
| Mallinckrodt Enterprises LLC | $246.16 | 2019 | |
| Argenx US, INC. | $245.00 | 2025 | Vyvgart Hytrulo |
| Sandoz INC. | $237.75 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $189.30 | 2023-2024 | Idacio |
| Octapharma USA, INC. | $159.28 | 2022-2023 | Octagam Immune Globulin (Human) |
| Organon LLC | $157.17 | 2023-2025 | Renflexis, Hadlima |
| Aurinia Pharma U.S., INC. | $144.31 | 2021-2023 | Lupkynis |
| Pacira Therapeutics, INC. | $127.16 | 2019-2021 | |
| Radius Health, INC. | $121.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.78 | 2022-2024 | Cuvitru, Hyqvia |
| Azurity Pharmaceuticals, INC. | $85.66 | 2023-2024 | Horizant, Horizant |
| Jazz Pharmaceuticals INC. | $77.20 | 2019-2021 | |
| Celgene Corporation | $75.05 | 2019 | |
| Sobi, INC | $74.54 | 2019-2025 | |
| Antares Pharma, INC. | $71.26 | 2019 | |
| Kyowa Kirin, INC. | $64.93 | 2024 | Crysvita |
| Scilex Pharmaceuticals INC. | $62.69 | 2024 | |
| Alvogen INC | $51.38 | 2022-2024 | Teriparatide |
| Celltrion USA INC. | $48.63 | 2023 | Yuflyma |
| Medexus Pharma, INC. | $36.72 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.42 | 2022 | |
| Merck Sharp & Dohme LLC | $23.74 | 2019 | |
| Eisai INC. | $23.52 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.41 | 2023 | Relistor |
| Fidia Pharma USA INC. | $19.40 | 2024 | Hyalgan, Triluron, Hymovis |
| Ibsa Pharma INC. | $13.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.11 | 2020 | |
| Currax Pharmaceuticals LLC | $11.14 | 2019 | |
| Biodelivery Sciences International, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lavery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.